Cancer Biomarkers Market Forecast and Trends
The global Cancer Biomarkers
market has reached 13.065 Billion in 2019 and estimated to reach USD 29.45
Billion in 2026 and anticipated to grow by CAGR of 12.61% during the forecast
period 2020-2026. The growth of the market is upheld by the surging prevalence
of cancer, coupled with the rising awareness about the usage of biomarkers at
several stages of cancer. Lack of physical activities, frequent sun & U.V.
exposure, improper diet, and growing consumption of tobacco are some of the
essential factors that have attributed to the escalating prevalence of cancer.
Around 22% of cancer deaths are caused due to tobacco consumption and are
regarded as the principal risk factor for cancer. Besides, few internal factors
such as hormonal imbalance, genetic mutation, and metabolic mutation contribute
towards the surge in cancer cases, which in turn boosts the demand for cancer
Moreover, the rising demand
for clinical diagnosis in cancer’s early stages and growing geriatric
population base further propels the usage rates of cancer biomarkers. Surging
utilization of the biomarkers in surrogate endpoints & drug targets
developments, increasing interest among researchers & students regarding
cancer diagnostic researchers, and increasing need for the biomarkers in cancer
research are few crucial success factors for the growth of the global cancer
Cancer Biomarkers Market Overview:
Cancer biomarkers are
chemicals that are released during the presence of a tumor, or a clear
indicator of cancer in the body. These are either a liquid, a molecule, or a
physical occurrence that indicates the presence of cancerous cells in the body.
These molecules are generally found in urine, tissues, blood, serum, and other
body fluids that indicate any unusual method or a disease. Cancer biomarkers
are traceable substances that can be used as a biological tumor status
indicator and thus can be used to assess cancer diagnostic and prognostic
levels. Cancer prevention by diagnosing and evaluating various biomarkers of
cancer using specific diagnostic techniques is a profound method for achieving
rapid treatment outcomes.
There have been significant
technological developments over fields such as diagnostic imaging,
immunoassays, omics technologies, and bioinformatics. Using advanced
bioinformatics tools, developments in omics technology allow faster acquisition
of proteomic, genomic, and metabolomics data and its alliance with clinical
trial data. Over the past decade, the omics movement has growing biomarker
applications in biomedical research. Additionally, developments in
high-throughput genomic technologies facilitate the identification and analysis
of crucial gene mutations and polymorphisms, thereby expanding the spectrum of
available genomic biomarkers.
Increased incidence and
prevalence of different types of cancer
There is a surge in the
cases of cancer among the global population has boosted the demand for the
Cancer Biomarkers. As per the World Health Organization, it is anticipated to
increase cancer cases over the next two decades further. Cancer is mainly
prevalent in lower and middle-income nations since they lack suitable
healthcare infrastructure to combat the condition effectively. Besides, the
cancer cases were higher in men than in women.
Technical issues concerning
collection and storage of samples
Most epidemiological studies
use biomarkers to examine various stages of human disease. It requires careful
handling and storage of sensitive biological samples to obtain a great deal of
information from small samples and reduce future research costs by using banked
samples. Also, risk detection, screening, diagnosis, and monitoring processes
require different samples. Furthermore, for proper sample handling and
management, detailed tracking, specimen storage, and recovery software are
needed. Such problems are expected to hamper the overall market growth of
Cancer Biomarkers Market: Type
Based on Type, the Cancer
Biomarkers market segmented into Protein Biomarker, Genetic Biomarker, and
Others (cell, viral, and carbohydrate biomarkers). The genetic biomarker
segment is forecasted to dominate during the forecast period, owing to the
advancement of technologies to detect the mutation. Gene expression profiling
(microarray), Next-generation sequencing (NGS), and polymerase chain reaction
(PCR) are the essential technologies used for genetic biomarker discovery and
diagnosis. Advancements in high-throughput technologies are the major factors
driving the cancer biomarkers market.
Cancer Biomarkers Market: Cancer Type
Based on Cancer Type, the
Cancer Biomarkers market segregated into Breast Cancer, Lung Cancer, Colorectal
Cancer, Prostate Cancer, Thyroid Cancer, Bladder Cancer, Kidney Cancer, and
Others. The lung cancer segment is projected to have a higher CAGR during the
forecast horizon due to the increase in the number of new lung cancer cases.
The growing focus by the company on research on lung cancer biomarkers is
another major factor for market growth. The increased understanding of the
morphology of lung carcinogenesis, the development of high-throughput
techniques for biomarker discovery, and increased focus on early detection of
cancer are also thrusting the market growth.
Cancer Biomarkers Market: Profiling Technology
Based on Profiling
Technology, the Cancer Biomarkers market segmented into Omics Technologies,
Imaging Technologies, Immunoassays, Cytogenetics, Bioinformatics, and Others.
The bioinformatics segment is predicted to grow at a very high CAGR during the
forecast period since it helps in the identification of robust and biomedically
significant biomarkers. Data mining also allows tools for the interpretation
and evaluation of the resulting models and predictions as well as the methods
to support the implementation of prophecy explanation mechanisms. Furthermore,
technological advancements, an expansion in demand for the development of new
drugs and clinical diagnostic tests, and the burgeoning information technology
industry in developing nations, such as India and China, are driving the
bioinformatics applications in biomarker discovery and development.
Cancer Biomarkers Market: Application
Based on Application, the
Cancer Biomarkers market segmented into Diagnostics, Drug Discovery &
Development, Prognostics, Risk Assessment, and Others. Drug Discovery &
Development segment is expected to record the highest CAGR during the forecast
period since it facilitates a better understanding of diseases during target
discovery. It plays a significant role in guiding decisions in every phase of
drug development—from drug discovery and preclinical evaluations to clinical
trials. The Application of biomarkers helps confirm the efficiency and safety
of drug candidates, get their mechanisms of action, and determine an effective
dose regime. This is resulting in the growth of this segment.
Cancer Biomarkers Market: Regional insights
By geography, the global
Cancer Biomarkers Market segregated into North America, Europe, Asia Pacific,
Middle East & Africa, and Latin America. North America is expected to have
the lion's share in the global cancer biomarkers market during the forecast
period, owing to the adoption of advanced technologies, increasing the number
of research studies for the development of novel biomarkers. The existence of a
large number of pharmaceutical firms, rising funding and investments from
public and private organizations, and the growing use of biomarkers in patient
stratification and drug development method.
Biomarkers Market: Competitive Landscape
The major market players in
the Global Cancer Biomarkers are Thermo Fisher Scientific, Bio-Rad
Laboratories, Roche Diagnostics, Qiagen N.V., Illumina, GE Healthcare, Agilent
Technologies, Biomérieux SA, Merck & Co., Abbott Laboratories, Becton,
Dickinson and Company, Danaher Corporation, Myriad Genetics, Sysmex
Corporation, Hologic, Quest Diagnostics, and other Prominent Players are
expanding their presence in the market by implementing various innovations and
objective of the Study:
To analyze and forecast the
global Cancer Biomarkers market size of the market in terms of value.
To examine the careful
market segmentation and forecast the market size, in terms value, based on the
region by segmenting the Global Cancer Biomarkers market into five regions,
namely, North America, Europe, Asia Pacific, Latin America, and the Middle East
& Africa and their leading countries.
To outline, categorized, and
forecast the global Cancer Biomarkers market based on Type, Cancer Type,
Profiling Technology, and Application.
To examine competitive
developments like technological advancement, services, and regulative framework
within the global Cancer Biomarkers Market.
To highlight the impact
analysis of the factors affecting the market dynamics such as drivers,
restraints, opportunities, and challenges.
To strategically profile the
key players and comprehensively analyze their market shares along with
detailing the competitive landscape for market leaders.
of the Report:
Historical data – 2016-2019
Base Year – 2019
Forecast – 2020 – 2026
Revenue in USD Million/Billion
U.S, Canada, Germany, UK, France, Italy, Spain, Brazil, Mexico,
Argentina, Japan, South Korea, China, India, UAE, South Africa, Saudi Arabia
By Type, Cancer Type, Profiling Technology,
Thermo Fisher Scientific, Bio-Rad Laboratories, Roche
Diagnostics, Qiagen N.V., Illumina, GE Healthcare, Agilent Technologies,
Biomérieux SA, Merck & Co., Abbott Laboratories, Becton, Dickinson and
Company, Danaher Corporation, Myriad Genetics, Sysmex Corporation, Hologic,
Quest Diagnostics, and other Prominent Players.
Others (cell, viral, and carbohydrate
By Cancer Type
By Profiling Technology
Drug Discovery & Development
Middle East & Africa
Questions answered by the report
How will the market drivers,
restraints, and opportunities affect the market dynamics?
What will be the market size
in terms of value and volume and market statistics with a detailed
Which segment dominates the
market or region, and one will be the fastest-growing, and why?
A comprehensive survey of
the competitive landscape and the market participant players
Analysis of strategy adopted
by the key player and their impact on other players.
Scope for the Client
Client satisfaction is our
first and last priority, and that is why BlueWeave Consulting offers
customization according to the company’s specific needs. The following
customization options are available for the report:
With five additional company
Additional country analysis
Detailed segment analysis